NASDAQ:QTRX - Quanterix Stock Price, Price Target & More

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix Corp. (NASDAQ:QTRX) announced its earnings results on Wednesday, May, 9th. The company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.08. View Quanterix's Earnings History.

4 brokerages have issued twelve-month price objectives for Quanterix's stock. Their forecasts range from $26.00 to $27.00. On average, they expect Quanterix's stock price to reach $26.50 in the next year. View Analyst Ratings for Quanterix.

Some companies that are related to Quanterix include Accelerate Diagnostics (AXDX), Pacific Biosciences (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), pSivida (EYPT), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Arrayit Corp common stock (ARYC), Precipio (PRPO), Pressure BioSciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix's lock-up period expires on Tuesday, June 5th. Quanterix had issued 4,275,200 shares in its IPO on December 7th. The total size of the offering was $64,128,000 based on an initial share price of $15.00. After the expiration of Quanterix's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

News coverage about QTRX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quanterix earned a news sentiment score of 0.01 on Accern's scale. They also assigned press coverage about the company an impact score of 45.81 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Quanterix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (0.95%), BlackRock Inc. (0.92%), Millennium Management LLC (0.73%), Opaleye Management Inc. (0.68%), Northern Trust Corp (0.24%) and Citadel Advisors LLC (0.12%). Company insiders that own Quanterix stock include David R Walt, E Kevin Hrusovsky and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.

QTRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Park West Asset Management LLC. View Insider Buying and Selling for Quanterix.

QTRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Opaleye Management Inc., Northern Trust Corp, Citadel Advisors LLC, Schwab Charles Investment Management Inc. and California State Teachers Retirement System. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of QTRX stock can currently be purchased for approximately $20.08.

Quanterix has a market capitalization of $440.96 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe.

Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400.